Year-over-year earnings per share growth for the last twelve months: revance.com (RVNC)

Revance Therapeutics Inc - graphic logo of issuer RVNC

The expansion of Daxxify and new therapeutic targets are driving the growth of Revance Therapeutics (RVNC). The quarterly EPS growth rate demonstrates the dynamics of earnings per share, while 77.10 reflects the latest level of this metric. Revenues are based on demand from dermatologists and aesthetic clinics. Operational stability is supported by the US domestic market and a neutral geopolitical backdrop for the industry.

revance.com (RVNC) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 02/16/2025

Financial and market metric breakdowns for Revance Therapeutics (RVNC)

- company stock exchange capitalization indicators:
Initial company analysis:Revance Therapeutics
Finished products of Revance Therapeutics Inc

Revance Therapeutics (RVNC) expansion into the neuromodulator segment via the drug Daxxify is reflected in the quarterly EPS growth rate, which serves as an indicator of business scaling efficiency. This metric is based on a probabilistic recalculation of net income per share growth rates, where prolonged stagnation of the line signals the accumulation of a systemic imbalance, foreshadowing either a sharp price impulse or a deep capital correction.

Key competitors

KRYS: Quarterly EPS earnings growth|APGE - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Arcutis Biotherapeutics, Inc.|Year-over-year earnings per share growth for the last 12 months VCEL (Vericel)|Year-over-year earnings per share growth for the last twelve months Oruka Pharma (ORKA)|Year-over-year net earnings per share change for the last twelve months Sanara MedTech|Quarterly EPS earnings growth DBVT (DBV Technologies SA)|Solesence Inc (SLSN) - Earnings per share growth in annualized terms for the last twelve months|DERM: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months FBRX (Forte Biosciences)|Empro Group (EMPG) - Year-over-year earnings per share growth for the last twelve months|Net earnings per share growth for the trailing year Sol-Gel Technologies Ltd. SLGL|Year-over-year net earnings per share growth for the last 12 months AXIL|Year-over-year net earnings per share growth for the last 12 months Medicus Pharma Ltd. (MDCX)|Quarterly EPS earnings growth VRCA|Year-over-year earnings per share growth rate for the last twelve months HOTH|Year-over-year earnings per share growth for the last twelve months biofrontera-us.com BFRI|Year-over-year earnings per one share growth for the last 12 months VYNE|SNOA - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months QNRX (quoinpharma.com)|Azitra (AZTR) - Year-over-year earnings per share growth for the last twelve months|DRMA: Year-over-year earnings per share growth rate for the last twelve months|ELAB (Elevai Labs) - Quarterly EPS earnings growth